Litigation Details for Allergan, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2017)
✉ Email this page to a colleague
Allergan, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-09-08 |
| Court | District Court, D. Delaware | Date Terminated | 2018-11-26 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 8,664,215 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan, Inc. v. Aurobindo Pharma Ltd.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for Allergan, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-09-08 | 1 | infringement of U.S. Patent No. 8,664,215 (the “‘215 patent”) under the Patent Laws of the United States…expiration of Plaintiffs’ patent covering Lastacaft® and its use. A copy of the ‘215 patent is attached as Exhibit… Vistakon is the assignee of the ‘215 patent. The ‘215 patent discloses and claims methods of treating…concerning the ‘215 patent to the FDA in connection with NDA No. 022134, identifying it as a patent “with respect… the expiration of the ‘215 patent will directly infringe the ‘215 patent under 35 U.S.C. §271(a), will | External link to document | |
| 2017-09-08 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,664,215 B2. (lmm) (Entered:… 26 November 2018 1:17-cv-01290 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2018-11-19 | 53 | Aurobindo with infringement of U.S. Patent No. 8,664,215 (“the ‘215 patent”) in connection with Aurobindo’…expiration of the ‘215 patent was a technical act of infringement of that patent under 35 U.S.C. § 271…Court has subject matter jurisdiction over this patent infringement action (the “Action”) and personal…Aurobindo and any of the Plaintiffs regarding the ‘215 patent and/or an alcaftadine ophthalmic solution 0.25%…was a technical act of infringement of the ‘215 patent under 35 U.S.C. § 27l(e)(2)(A). No decision of | External link to document | |
| 2018-11-25 | 55 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,664,215 B2. (Attachments: #… 26 November 2018 1:17-cv-01290 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
